Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary. Bacsur P, Ilias A, Resal T, Kata D, et al. Aliment Pharmacol Ther 2023;58:262-263.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bacsur P, Ilias A, Resal T, Kata D, et al. Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary. Aliment Pharmacol Ther 2023;58:262-263.
PMID: 37352154